Akebia Therapeutics (AKBA) Reports Q4 results

Akebia Therapeutics (NASDAQ: AKBA) reported Q4 Revenue for the quarter at $56.2 million versus the consensus estimate of $55.89 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• ServiceNow (NOW) PT Raised to $155 at Needham
• RH (RH) Tops Q2 EPS by $2.31